Prevail Therapeutics Seeking to Bring Gene Therapy PR001 to Parkinson Disease With Phase 1/2a PROPEL Clinical Trial
Eli Lilly and Company subsidiary Prevail Therapeutics’ PR001 (also known as LY3884961), an investigational adeno-associated virus serotype 9 (AAV9) vector-based gene therapy, is currently being evaluated for the treatment of patients with Parkinson disease …